Exosomes derived from lung cancer cells: Isolation, characterization, and stability studies

Eur J Pharm Sci. 2023 Feb 1:181:106369. doi: 10.1016/j.ejps.2022.106369. Epub 2022 Dec 24.

Abstract

Recent advances in nanomedicine have paved the way for developing targeted drug delivery systems. Nanoscale exosomes are present in almost every body fluid and represent a novel mechanism of intercellular communication. Because of their membrane origin, they easily fuse with cells, acting as a natural delivery system and maintaining the bioactivity and immunotolerance of cells. To develop a reconstitutable exosome-based drug candidate for clinical applications, quality assurance by preserving its physical and biological properties during storage is necessary. Therefore, this study aimed to determine the best storage conditions for exosomes derived from lung cancer cells (A549). This study established that the phosphate-buffered saline buffer enriched with 25 mM trehalose is an optimal cryoprotectant for A549-derived exosomes stored at -80°C. Under these conditions, the concentration, size distribution, zeta potential, and total cargo protein levels of the preserved exosomes remained constant.

Keywords: Exosome; Lung cancer; Preservatives; Stability; Storage conditions.

MeSH terms

  • Cryoprotective Agents
  • Drug Delivery Systems
  • Exosomes* / metabolism
  • Humans
  • Lung Neoplasms* / metabolism
  • Trehalose

Substances

  • Cryoprotective Agents
  • Trehalose